Abstract Number: 1403 • 2015 ACR/ARHP Annual Meeting
Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review of Case Reports
Background/Purpose: Background: The recent discovery of the immune checkpoint blockade that targets the regulatory pathways in T cells to enhance antitumor immune responses has led…Abstract Number: 1488 • 2015 ACR/ARHP Annual Meeting
Following the American College of Rheumatology Quality Guidelines Can Enhance the Safety of Rheumatoid Arthritis Patients Treated with Disease Modifying Drugs
Background/Purpose: Adverse events (AEs) and serious adverse events (SAEs) from disease modifying drugs (DMARDs) for Rheumatoid Arthritis (RA) can result in significant morbidity and even…Abstract Number: 1538 • 2015 ACR/ARHP Annual Meeting
Clinical Analysis of 30 Rheumatoid Arthritis Patients Complicated with Malignant Lymphoma, Especially Methotrexate-Related Lymphoproliferative Disorder
Background/Purpose: Recently, methotrexate (MTX) has been considered as the anchor drug in the treatment of rheumatoid arthritis (RA). However, it has been reported that MTX…Abstract Number: 1631 • 2015 ACR/ARHP Annual Meeting
Adverse Events to Biologic Agents in Elderly Patients with Rheumatoid Arthritis: Cohort with 13 Years of Follow-up
Background/Purpose: After more than a decade using biological agents (BA), is widely known their efficacy in the treatment of Rheumatoid Arthritis (RA) and their relationship…Abstract Number: 2109 • 2015 ACR/ARHP Annual Meeting
Racial Disparities in the Risk of Hospitalized Severe Allopurinol Hypersensitivity Syndrome – a US Nationwide Study (2009-2011)
Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy for gout (>95% of treated cases); however, it is associated with the rare but potentially fatal…Abstract Number: 2140 • 2015 ACR/ARHP Annual Meeting
Drug Specific Risk and Associated Factors for Vasculitis-like Events in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose: The association between TNF inhibitors (TNFis) and vasculitis-like events, possibly secondary to induction of autoantibodies, has been well reported. However, the incidence, drug-specific differences…Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…Abstract Number: 443 • 2015 ACR/ARHP Annual Meeting
Drug Survival and Reasons for Discontinuation of Biological Disease Modifying Antirheumatic Drug in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization (RDPA) Register
Background/Purpose: To evaluate long-term efficacy and safety of biological disease modifying antirheumatic drug (bDMARD) in real-life practice and identify risk factors related to remission and drug discontinuation…Abstract Number: 2167 • 2015 ACR/ARHP Annual Meeting
Application of Combined Reporting of Benefit and Harm (OMERACT 3×3 methodology) to the Rheumatoid Arthritis Comparison of Active Therapies Trial
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Initiative has suggested an analysis of the occurrence of benefit and harm in trials simultaneously, at the individual…Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…Abstract Number: 1838 • 2014 ACR/ARHP Annual Meeting
No Increased Risk of Developing a First Invasive Melanoma in Rheumatoid Arthritis Patients Treated with Biologics: Results of a Collaborative Project of 11 European Biologics Registers
Background/Purpose: Swedish and Danish national biologics registers (*) have reported a possible increase in melanoma risk with TNF inhibitors. Since melanomas are uncommon, the association…Abstract Number: 1800 • 2014 ACR/ARHP Annual Meeting
Objectively Measured Sedentary Behavior Is a Distinct Risk Factor from Low Moderate-to-Vigorous Activity in Predicting Subsequent Frailty: Evidence from Osteoarthritis Initiative
Background/Purpose: Physical frailty represents a state of high vulnerability for adverse health outcomes including disability and mortality. Physical activity interventions to improve health have largely…Abstract Number: 1319 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Treating Pediatric Rheumatologic Disease
Background/Purpose Rituximab is a chimeric human/murine monoclonal antibody directed against the B cell specific antigen CD20. There is growing evidence that suggests Rituximab may also…Abstract Number: 848 • 2014 ACR/ARHP Annual Meeting
Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients
Background/Purpose Recent studies have found that a high proportion of female rheumatoid arthritis (RA) patients are chronic carriers of high-risk HPV-strains and that these patients…Abstract Number: 503 • 2014 ACR/ARHP Annual Meeting
Does a Higher Dose of Folic Acid Reduce Adverse Effects of Methotrexate in Rheumatoid Arthritis? a Randomized Controlled Trial
Background/Purpose There is good evidence that folic acid 5-10mg per week leads to reduction in methotrexate (MTX) toxicity in rheumatoid arthritis (RA). However, this data…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- Next Page »